ArticlePharmacoEconomics - open2022

Cost Effectiveness of Subcutaneous Vedolizumab for Maintenance Treatment of Ulcerative Colitis in Canada.

Elisabetta Fenu et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.